Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a reorganization of the management team in order to streamline and increase operational focus. After the change the company´s management team consists of 6 people, including the CEO, vs. previously 8 people. Two new functions are created: Strategic Business Development, which is a consolidation of Corporate Development and Business Development, and Finance & Administration, which is a consolidation of the current Finance & Administration function and Corporate Affairs & IR.
- I want to create a smaller and more effective management team with fewer and stronger functions. With the structure and composition of the management team now being presented, I am convinced that we will be able to work in a more focused way and deliver better results in the implementation of the updated strategy and in the leadership of the company, says Niklas Prager, CEO Medivir AB.
The management team will be strengthened with two new colleagues with long experience from strategic business development as well as finance. Christine Lind has been recruited as new head of Strategic Business Development. New CFO, with responsibility also for IR, will be Ola Burmark.
Christina Kassberg, Rein Piir, Paul Wallace and Håkan Wallin have chosen to leave the company by the end of February. The new organization will be effective on March 1, 2015.
- I would like to take this opportunity to thank the four colleagues that are leaving the company for their great dedication and valuable contributions throughout the years, Niklas Prager continues.
For more information please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.
Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals.
Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, OLYSIO®. In addition, revenues for sales of OLYSIO in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science. The company’s research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.